Skip to content
World City Press – Lifestyle
Author:
AbbVie
AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026
September 30, 2026
AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress
September 30, 2026
AbbVie Partners with Valkai to Apply Advanced AI Across Targeted Areas of Clinical Development
September 29, 2026
U.S. FDA Approves AbbVie’s JUVMO™ (tavapadon) for Parkinson’s Disease
September 28, 2026
Allergan Aesthetics Debuts AA Signature™ in the United States with SKIN360, Its First Multimodal Consultation Approach
September 22, 2026
AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritis
September 22, 2026
AbbVie and Iambic Announce Collaboration to Accelerate AI-driven Drug Discovery
September 21, 2026
AbbVie Highlights New Real-World Data Supporting the Effectiveness of VRAYLAR® (cariprazine) at Psych Congress 2026
September 18, 2026
AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society (IMS) Meeting
September 17, 2026
Allergan Aesthetics Presents New Clinical Data Evaluating Skin Quality Improvements in Individuals Taking Medical Weight Loss Medications
September 17, 2026
1
2
3
…
5
Next Page
→